Theranos
Amount undisclosed
Funding date
Valuation / Funding
| Date | Round | Amount | Post-Valuation | Growth |
|---|---|---|---|---|
| N/A | Unknown | Undisclosed | N/A | - |
Current Valuation Metrics
Theranos is currently valued at N/A.
Investment Perspective
Theranos's valuation reflects investor confidence in the company's market position, growth potential, and ability to execute on its business model. Private market valuations are determined by primary funding rounds and secondary market transactions, which take into account financial performance, market conditions, and growth prospects.
What is Theranos Worth in 2025?
As of 2025, Theranos is valued at N/A. This valuation positions Theranos as one of the leading private companies in the sector.
Theranos Valuation History
Theranos has completed 1 funding round.
How Theranos Valuation is Determined
Private company valuations like Theranos's are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including:
- Revenue growth and financial performance
- Market opportunity and total addressable market (TAM)
- Competitive positioning and market share
- Management team strength and execution capability
- Technology and intellectual property
- Industry trends and investor sentiment
Theranos Valuation FAQs
Is Theranos profitable?
Theranos has not publicly disclosed its profitability status. Many high-growth private companies prioritize market expansion and user growth over profitability in their early stages.
How does Theranos's valuation compare to competitors?
Theranos is valued at N/A, positioning it as a major player in the space. Secondary market pricing and private market transactions provide ongoing validation of this valuation.
When will Theranos IPO?
Theranos has not announced plans for an initial public offering. Until an IPO, investors can access Theranos shares through secondary market platforms.